Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The ganglionic nicotinic acetylcholine receptor (gAChR) is a pentameric ligand-gated ion channel that serves as the primary mediator of fast synaptic transmission within the autonomic nervous system (PubMed ID: 18567861, 11005892). These receptors are situated on the postsynaptic membranes of neurons in sympathetic, parasympathetic, and enteric ganglia and are predominantly composed of alpha-3 and beta-4 subunits (PubMed ID: 17405096). Upon binding of acetylcholine released from preganglionic fibers, the gAChR opens to allow an influx of cations, leading to neuronal depolarization and the propagation of autonomic signals that regulate heart rate, vascular tone, and visceral motility (PubMed ID: 18567861). In the disease state of autoimmune autonomic ganglionopathy (AAG), the receptor is targeted by pathogenic autoantibodies, causing comprehensive autonomic failure (PubMed ID: 11005892). While ganglionic blockers like hexamethonium and mecamylamine were historically the first effective treatments for hypertension, their non-selective blockade of both autonomic branches causes significant side effects, such as orthostatic hypotension and dry mouth, which has largely restricted their modern clinical application (Wikipedia: Ganglionic blocker).
Binding to the ganglionic nicotinic acetylcholine receptor to either antagonize (blockade) or agonize (stimulate) fast synaptic transmission between pre- and postganglionic autonomic neurons.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ganglionic nicotinic acetylcholine receptor (gAChR) (gAChR).